Indian patentability refined, post-Glivec
The Novartis decision on April 1 2013 turned the spotlight on section 3(d) of India’s Patent Act. A year on, Meenakshi Khurana looks at how this doctrine, along with obviousness standards, have been interpreted in recent cases
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
